ReviewCureus2026
Frailty Screening and Prehabilitation Before Kidney Transplant Listing: A Practical Narrative Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sarcopenia in Kidney Transplantation: Bridging Pathophysiology to Patient-Centered Care.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Frailty is increasingly recognized as a clinically meaningful and potentially modifiable vulnerability among kidney transplant candidates and among patients with advanced chronic kidney disease (CKD) referred for transplant evaluation. Contemporary guidance emphasizes individualized risk-benefit assessment and equity in access to transplantation while acknowledging substantial inter-center variability in evaluation practices. Frailty assessment may improve transparency and consistency compared with subjective impressions, support shared decision-making, and identify targets for prehabilitation and other optimization strategies. However, challenges persist, including heterogeneity in frailty definitions, variability in reported frailty prevalence across transplant-candidate cohorts and instruments, uncertainty regarding optimal tools and thresholds, and operational questions regarding who should measure frailty, when to repeat testing, and how to interpret results without creating unjust barriers to listing. This narrative review summarizes (i) conceptual models of frailty relevant to transplant candidates, (ii) practical frailty assessment options and their feasibility in transplant clinics, (iii) a pragmatic workflow for integrating frailty screening into pre-listing evaluation, and (iv) evidence and implementation considerations for prehabilitation in kidney transplant candidates. Overall, frailty screening is best positioned as a tool for decision-support and targeted optimization rather than a rigid exclusion criterion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.